Latest Regurgitation Stories

OR YEHUDA, Israel, May 16, 2013 /PRNewswire/ -- Valtech Cardio Ltd., a medical device company that develops solutions for mitral valve repair and replacement, announced today that two patients diagnosed with severe mitral regurgitation (MR) have been treated successfully with the Transfemoral Cardioband(TM) Annuloplasty System. (Photo: http://photos.prnewswire.com/prnh/20130516/613819 ) The Cardioband device replaces the need for open-heart surgery for MR...

ABBOTT PARK, Ill., March 20, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits of treatment with the MitraClip(®) device outweigh its risks in patients with significant symptomatic mitral regurgitation (MR) who have been determined by a cardiac surgeon to be too high risk for open mitral valve...

Third European Multi-Center Study Validating Earlier Compelling Results KIRKLAND, Wash., March 8, 2013 /PRNewswire/ -- Cardiac Dimensions(®),( )Inc. today announced that it has completed enrollment in its TITAN II clinical trial, a follow-up to the landmark TITAN clinical trial of the Company's CARILLON(® )Mitral Contour System(®). TITAN II is a prospective, single-arm European multi-center clinical trial initiated to further evaluate an enhanced version of the...

CHICAGO, Jan. 14, 2013 /PRNewswire/ -- Phoenix Cardiac Devices, Inc., a medical device company with a novel method of repairing leaky heart valves without open-heart surgery, has enrolled its first patient in a clinical trial aimed at achieving CE Mark approval in Europe. The trial will assess the safety and efficacy of the BACE(TM) device, an adjustable tension band that encircles the heart and supports the mitral valve leaflets so they close properly to prevent the back flow of...

KIRKLAND, Wash., Sept. 28, 2012 /PRNewswire/ --Cardiac Dimensions(®),( )Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON® Mitral Contour System® under its Conformite Europeenne (CE) Mark approval. The CARILLON system is a novel, minimally invasive therapy for treating heart patients suffering from functional mitral regurgitation (FMR). An estimated 70 percent of the 20 million people worldwide with heart...

--"Encouraging" Short-Term Data from Innovative Product to Treat Mitral Regurgitation Using Transcatheter Approach-- --Chronic Animal Studies Underway in Preparation for Potential First Human Implantations in 2013-- TSX Venture Exchange: NVC VANCOUVER, Sept. 18, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that acute results from preclinical studies of its Tiara(TM )valve for the transcatheter treatment of mitral regurgitation were published in the...

WEST BRIDGEWATER, Mass., July 10, 2012 /PRNewswire/ -- Cardiosolutions, Inc. an early-stage company focused on the development of an innovative percutaneous system to treat patients with moderate to severe mitral valve regurgitation, today announced it has received a minority investment from Sorin Group (Reuters Code: SORN.MI), a global medical device company and an international leader in the treatment of cardiovascular disease. Cardiosolutions' technology consists of a...

MISGAV, Israel, June 4, 2012 /PRNewswire/ -- MitrAssist Medical Ltd., a developer of minimally invasive products for treating heart disease, announced today that it received ISO 13485:2003 Certification for the design and development of implantable heart valve prostheses. Today's standard treatment for mitral valve regurgitation (MR), blood leakage or backflow into the atrium, is open heart surgery. MitrAssist's unique design preserves the ventricular dynamic mode of...

KIRKLAND, Wash., May 21, 2012 /PRNewswire/ -- Cardiac Dimensions®,( )Inc. today announced that data from its landmark TITAN clinical trial has been published in the most recent issue of the European Journal of Heart Failure. Titled "Treatment of Functional Mitral Regurgitation by Percutaneous Annuloplasty: Results of the TITAN Trial," the manuscript features two-year follow-up data on patients implanted with the CARILLON® Mitral Contour System® as well as one-year follow-up on...

--Presentations will Highlight Promising Results from Animal Studies-- TSX Venture Exchange: NVC VANCOUVER, May 14, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies to treat vascular disease, today announced that its Tiara(TM) technology under development for the transcatheter treatment of mitral valve disease will be featured in three scientific sessions at EuroPCR 2012, the annual meeting of the European Association for Percutaneous...